Skip to content
1st Counsel – Lifestyle
Author:
Revier Therapeutics GmbH
Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease
August 25, 2026